Minerva Surgical Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Darrin Hammers

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	1.8yrs

Recente managementupdates

Recent updates

Is There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 44% Undervaluation?

Aug 11

Minerva downgraded at JPMorgan citing lowered guidance

Aug 10

Minerva Surgical, Inc. (NASDAQ:UTRS) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 10

Minerva Surgical - Uterine Play For Sale

Nov 02

CEO

Darrin Hammers

less than a year

Tenure

Mr. Darrin Hammers is Chief Executive Officer of Minerva Surgical, Inc. from August 2024. He has certain years of leadership experience in the medical device industry and he has been President and Chief Ex...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Darrin Hammers	Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Greg Simbro	Vice President of Finance	less than a year	geen gegevens	geen gegevens
Erik Reese	Vice President of Sales	less than a year	geen gegevens	geen gegevens
Wendy Bowman	Vice President of Human Resources	no data	geen gegevens	geen gegevens
Evgueni Skalnyi	Chief Medical Officer	1.8yrs	US$388.99k	geen gegevens
Brent Palmisano	Chief Commercial Officer	no data	geen gegevens	geen gegevens
Joanne Long	Vice President of Corporate Controller	3.8yrs	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van UTRS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Uri Geiger	Director	1.8yrs	geen gegevens	geen gegevens
Catherine Coste	Independent Director	3.8yrs	US$187.50k	0.067% $ 0.005
Daniel Cohen	Independent Director	1.8yrs	geen gegevens	0% $ 0

1.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van UTRS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.

Minerva Surgical Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Minerva Surgical, Inc. Announces the Resignation of Jill D. Anderson from the Board of Directors

Minerva Surgical, Inc. Announces Resignation of Ross A. Jaffe from the Board and from the Compensation Committee of the Board

High number of new directors

Minerva Surgical, Inc. Announces Resignation of David M. Renzi from Board of Directors and as Chairman of its Nominating and Corporate Governance Committee

Minerva Surgical, Inc. Announces Management Changes

Minerva Surgical, Inc. Appoints Derrick Sung as Director

Recent updates

Minerva Surgical Files Form 15

Minerva Surgical, Inc.(OTCPK:UTRS) dropped from NASDAQ Composite Index

Minerva Surgical, Inc. Announces Voluntary SEC Deregistration and Nasdaq Delisting

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Minerva Surgical, Inc. Announces the Resignation of Jill D. Anderson from the Board of Directors

Minerva Surgical, Inc. announced that it expects to receive $20 million in funding from Accelmed Partners

Consensus EPS estimates upgraded to US$0.22 loss

Minerva Surgical, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Minerva Surgical, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Minerva Surgical, Inc. Announces Resignation of Ross A. Jaffe from the Board and from the Compensation Committee of the Board

Minerva Surgical Provides Revenue Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings released: US$1.18 loss per share (vs US$3.06 loss in FY 2021)

Minerva Surgical, Inc. announced that it has received $30 million in funding from Accelmed Partners, New Enterprise Associates, Inc.

High number of new directors

Minerva Surgical, Inc. Announces Resignation of David M. Renzi from Board of Directors and as Chairman of its Nominating and Corporate Governance Committee

Minerva Surgical Receives Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

Minerva Surgical, Inc. Announces Management Changes

Minerva Surgical, Inc. announced that it expects to receive $30 million in funding from Accelmed Partners, New Enterprise Associates, Inc.

Consensus forecasts updated

Minerva Surgical, Inc. Provides Revenue Guidance for 2022

Third quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$5.00

Minerva Surgical Receives Notification Regarding Minimum Bid Price from the Listing Qualifications Department of the Nasdaq

Minerva Surgical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

U.S. Court of Appeals for the Federal Circuit Affirms Ruling on Minerva Surgical, Inc. and Hologic, Inc. Case

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 44% Undervaluation?

Minerva downgraded at JPMorgan citing lowered guidance

Minerva Surgical, Inc. Revises Revenue Guidance for the Year 2022

Minerva Surgical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Minerva Surgical, Inc. Appoints Derrick Sung as Director

Minerva Surgical, Inc.(NasdaqGM:UTRS) dropped from Russell Microcap Value Index

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Minerva Surgical, Inc. Provides Earnings Guidance for 2022

Minerva Surgical, Inc., Annual General Meeting, Jun 09, 2022

Minerva Surgical, Inc. Provides Revenue Guidance for the Full Year 2022

Minerva Surgical, Inc. (NASDAQ:UTRS) Just Reported Earnings, And Analysts Cut Their Target Price

Full year 2021 earnings: EPS exceeds analyst expectations

Minerva Surgical, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Minerva Surgical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

President recently bought US$123k worth of stock

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Minerva Surgical, Inc. Provides Revenue Guidance for the Full Year 2021

Minerva Surgical - Uterine Play For Sale

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd